O	0	9	Titration	Titration	NN	B-NP
O	10	12	of	of	IN	B-PP
O	13	15	Ab	Ab	NN	B-NP
O	15	16	-	-	HYPH	O
O	16	18	01	01	CD	B-NP
O	19	29	inhibition	inhibition	NN	I-NP
O	30	32	of	of	IN	B-PP
O	33	35	ex	ex	FW	B-NP
O	36	40	vivo	vivo	FW	I-NP
O	41	49	response	response	NN	I-NP
O	50	52	to	to	TO	B-PP
O	53	59	rhIL21	rhIL21	NN	B-NP

B-Organism_substance	60	67	Samples	Sample	NNS	B-NP
O	68	72	from	from	IN	B-PP
O	73	74	4	4	CD	B-NP
O	75	85	individual	individual	JJ	I-NP
O	86	93	healthy	healthy	JJ	I-NP
O	94	99	human	human	JJ	I-NP
O	100	106	donors	donor	NNS	I-NP
O	107	111	were	be	VBD	B-VP
O	112	115	pre	pre	AFX	B-ADJP
O	115	116	-	-	HYPH	B-NP
O	116	125	incubated	incubate	VBN	B-VP
O	126	129	for	for	IN	B-PP
O	130	131	2	2	CD	B-NP
O	132	137	hours	hour	NNS	I-NP
O	138	140	at	at	IN	B-PP
O	141	144	the	the	DT	B-NP
O	145	154	indicated	indicate	VBN	I-NP
O	155	168	concentration	concentration	NN	I-NP
O	169	171	of	of	IN	B-PP
O	172	174	Ab	Ab	NN	B-NP
O	174	175	-	-	HYPH	O
O	175	177	01	01	CD	B-NP
O	178	180	or	or	CC	O
O	181	184	the	the	DT	B-NP
O	185	192	control	control	NN	I-NP
O	193	199	IgG1TM	IgG1TM	NN	I-NP
O	200	205	prior	prior	JJ	B-ADJP
O	206	208	to	to	TO	B-PP
O	209	217	addition	addition	NN	B-NP
O	218	220	of	of	IN	B-PP
O	221	223	10	10	CD	B-NP
O	224	226	ng	ng	NN	I-NP
O	226	227	/	/	SYM	O
O	227	229	mL	mL	NN	B-NP
O	230	236	rhIL21	rhIL21	NN	I-NP
O	237	240	and	and	CC	O
O	241	242	2	2	CD	B-NP
O	243	245	hr	hr	NN	I-NP
O	246	256	incubation	incubation	NN	I-NP
O	256	257	,	,	,	O
O	258	261	and	and	CC	O
O	262	265	the	the	DT	B-NP
O	266	272	effect	effect	NN	I-NP
O	273	275	on	on	IN	B-PP
O	276	279	the	the	DT	B-NP
O	280	281	6	6	CD	I-NP
O	282	292	biomarkers	biomarker	NNS	I-NP
O	293	296	was	be	VBD	B-VP
O	297	301	then	then	RB	I-VP
O	302	310	assessed	assess	VBN	I-VP
O	311	312	(	(	(	O
O	312	319	Figures	Figure	NNS	B-NP
O	320	321	4	4	CD	B-NP
O	322	325	and	and	CC	I-NP
O	326	327	5	5	CD	I-NP
O	327	328	)	)	)	O
O	328	329	.	.	.	O

O	330	333	For	For	IN	B-PP
O	334	337	the	the	DT	B-NP
O	338	343	first	first	JJ	I-NP
O	344	345	2	2	CD	I-NP
O	346	352	donors	donor	NNS	I-NP
O	353	359	tested	test	VBN	B-VP
O	359	360	,	,	,	O
O	361	365	even	even	RB	B-NP
O	366	369	the	the	DT	I-NP
O	370	376	lowest	low	JJS	I-NP
O	377	390	concentration	concentration	NN	I-NP
O	391	393	of	of	IN	B-PP
O	394	396	Ab	Ab	NN	B-NP
O	396	397	-	-	HYPH	O
O	397	399	01	01	CD	B-NP
O	400	401	(	(	(	O
O	401	402	0	0	CD	B-NP
O	402	403	.	.	.	O
O	403	404	1	1	CD	B-NP
O	405	408	mug	mug	NN	I-NP
O	408	409	/	/	SYM	B-NP
O	409	411	mL	mL	NN	I-NP
O	411	412	,	,	,	O
O	413	414	0	0	CD	B-NP
O	414	415	.	.	.	O
O	415	417	66	66	CD	B-NP
O	418	420	nM	nM	NN	I-NP
O	420	421	)	)	)	O
O	422	430	resulted	result	VBD	B-VP
O	431	433	in	in	IN	B-PP
O	434	442	complete	complete	JJ	B-NP
O	443	453	inhibition	inhibition	NN	I-NP
O	454	456	of	of	IN	B-PP
O	457	460	the	the	DT	B-NP
O	461	467	rhIL21	rhIL21	NN	I-NP
O	468	476	response	response	NN	I-NP
O	476	477	,	,	,	O
O	478	487	therefore	therefore	RB	B-ADVP
O	488	491	the	the	DT	B-NP
O	492	495	two	two	CD	I-NP
O	496	506	subsequent	subsequent	JJ	I-NP
O	507	513	donors	donor	NNS	I-NP
O	514	518	were	be	VBD	B-VP
O	519	525	tested	test	VBN	I-VP
O	526	528	at	at	IN	B-PP
O	529	539	increasing	increase	VBG	B-VP
O	540	554	concentrations	concentration	NNS	B-NP
O	555	557	of	of	IN	B-PP
O	558	560	Ab	Ab	NN	B-NP
O	560	561	-	-	HYPH	B-NP
O	561	563	01	01	CD	I-NP
O	564	572	starting	start	VBG	B-VP
O	573	575	at	at	IN	B-PP
O	576	577	0	0	CD	B-NP
O	577	578	.	.	.	O
O	578	581	003	003	CD	B-NP
O	582	585	mug	mug	NN	I-NP
O	585	586	/	/	SYM	B-NP
O	586	588	mL	mL	NN	I-NP
O	588	589	.	.	.	O

O	590	592	Ab	Ab	NN	B-NP
O	592	593	-	-	HYPH	B-NP
O	593	595	01	01	CD	I-NP
O	596	605	inhibited	inhibit	VBD	B-VP
O	606	609	the	the	DT	B-NP
O	610	618	response	response	NN	I-NP
O	619	621	of	of	IN	B-PP
O	622	625	all	all	DT	B-NP
O	626	627	6	6	CD	I-NP
O	628	633	genes	gene	NNS	I-NP
O	634	636	in	in	IN	B-PP
O	637	640	all	all	DT	B-NP
O	641	642	4	4	CD	I-NP
O	643	649	donors	donor	NNS	I-NP
O	649	650	.	.	.	O

O	651	655	IC50	IC50	NN	B-NP
O	656	662	values	value	NNS	I-NP
O	663	669	ranged	range	VBD	B-VP
O	670	677	between	between	IN	B-PP
O	678	679	0	0	CD	B-NP
O	679	680	.	.	.	O
O	680	683	003	003	CD	B-NP
O	684	687	and	and	CC	I-NP
O	688	689	0	0	CD	I-NP
O	689	690	.	.	.	O
O	690	693	015	015	CD	B-NP
O	694	697	mug	mug	NN	I-NP
O	697	698	/	/	SYM	O
O	698	700	mL	mL	NN	B-NP
O	701	703	Ab	Ab	NN	I-NP
O	703	704	-	-	HYPH	O
O	704	706	01	01	CD	B-NP
O	706	707	(	(	(	O
O	707	713	Figure	Figure	NN	B-NP
O	714	715	5	5	CD	I-NP
O	715	716	)	)	)	O
O	716	717	.	.	.	O

O	718	725	Control	Control	NN	B-NP
O	726	732	IgG1TM	IgG1TM	NN	I-NP
O	733	736	had	have	VBD	B-VP
O	737	739	no	no	DT	B-NP
O	740	751	significant	significant	JJ	I-NP
O	752	758	effect	effect	NN	I-NP
O	759	761	on	on	IN	B-PP
O	762	768	rhIL21	rhIL21	NN	B-NP
O	769	777	response	response	NN	I-NP
O	778	779	(	(	(	O
O	779	787	Figure4B	Figure4B	NN	B-NP
O	787	788	)	)	)	O
O	788	789	.	.	.	O

O	790	796	Figure	Figure	NN	B-NP
O	797	798	4	4	CD	I-NP

O	799	806	Average	Average	JJ	B-NP
O	807	814	percent	percent	NN	I-NP
O	815	825	inhibition	inhibition	NN	I-NP
O	826	828	of	of	IN	B-PP
O	829	832	the	the	DT	B-NP
O	833	843	expression	expression	NN	I-NP
O	844	849	level	level	NN	I-NP
O	850	852	of	of	IN	B-PP
O	853	854	6	6	CD	B-NP
O	855	859	IL21	IL21	NN	I-NP
O	859	860	-	-	HYPH	B-NP
O	860	870	responsive	responsive	JJ	I-NP
O	871	876	genes	gene	NNS	I-NP
O	876	877	.	.	.	O

O	878	885	Percent	Percent	JJ	B-NP
O	886	896	inhibition	inhibition	NN	I-NP
O	897	903	values	value	NNS	I-NP
O	904	908	were	be	VBD	B-VP
O	909	919	calculated	calculate	VBN	I-VP
O	920	925	based	base	VBN	B-PP
O	926	928	on	on	IN	B-PP
O	929	931	RQ	RQ	NN	B-NP
O	932	933	(	(	(	O
O	933	941	relative	relative	JJ	B-NP
O	942	956	quantification	quantification	NN	I-NP
O	956	957	)	)	)	O
O	958	964	values	value	NNS	B-NP
O	965	967	of	of	IN	B-PP
O	968	977	untreated	untreated	JJ	B-NP
O	978	985	control	control	NN	I-NP
O	986	989	and	and	CC	I-NP
O	990	996	rhIL21	rhIL21	NN	I-NP
O	996	997	-	-	HYPH	B-NP
O	997	1004	treated	treat	VBN	I-NP
B-Organism_substance	1005	1012	samples	sample	NNS	I-NP
O	1013	1016	for	for	IN	B-PP
O	1017	1021	each	each	DT	B-NP
O	1022	1024	of	of	IN	B-PP
O	1025	1028	the	the	DT	B-NP
O	1029	1030	4	4	CD	I-NP
O	1031	1037	donors	donor	NNS	I-NP
O	1037	1038	,	,	,	O
O	1039	1042	and	and	CC	O
O	1043	1055	subsequently	subsequently	RB	B-ADVP
O	1056	1059	the	the	DT	B-NP
O	1060	1064	mean	mean	JJ	I-NP
O	1065	1068	and	and	CC	I-NP
O	1069	1077	standard	standard	JJ	I-NP
O	1078	1087	deviation	deviation	NN	I-NP
O	1088	1092	were	be	VBD	B-VP
O	1093	1103	determined	determine	VBN	I-VP
O	1104	1107	for	for	IN	B-PP
O	1108	1112	each	each	DT	B-NP
O	1113	1117	gene	gene	NN	I-NP
O	1118	1123	shown	show	VBN	B-VP
O	1123	1124	.	.	.	O

O	1125	1126	A	A	DT	B-NP
O	1126	1127	:	:	:	O
O	1128	1135	Percent	Percent	NN	B-NP
O	1136	1146	inhibition	inhibition	NN	I-NP
O	1147	1149	in	in	IN	B-PP
O	1150	1158	presence	presence	NN	B-NP
O	1159	1161	of	of	IN	B-PP
O	1162	1164	Ab	Ab	NN	B-NP
O	1164	1165	-	-	HYPH	B-NP
O	1165	1167	01	01	CD	I-NP
O	1167	1168	.	.	.	O

O	1169	1170	B	B	NN	B-NP
O	1170	1171	:	:	:	O
O	1172	1179	Percent	Percent	NN	B-NP
O	1180	1190	inhibition	inhibition	NN	I-NP
O	1191	1193	in	in	IN	B-PP
O	1194	1202	presence	presence	NN	B-NP
O	1203	1205	of	of	IN	B-PP
O	1206	1213	control	control	NN	B-NP
O	1214	1220	IgG1TM	IgG1TM	NN	I-NP
O	1220	1221	.	.	.	O

O	1222	1226	Data	Datum	NNS	B-NP
O	1227	1230	for	for	IN	B-PP
O	1231	1234	the	the	DT	B-NP
O	1235	1236	0	0	CD	I-NP
O	1236	1237	.	.	.	I-NP
O	1237	1238	1	1	CD	I-NP
O	1239	1242	mug	mug	NN	I-NP
O	1242	1243	/	/	SYM	B-NP
O	1243	1245	mL	mL	NN	I-NP
O	1246	1247	,	,	,	O
O	1248	1249	0	0	CD	B-NP
O	1249	1250	.	.	.	O
O	1250	1251	3	3	CD	B-NP
O	1252	1255	mug	mug	NN	I-NP
O	1255	1256	/	/	SYM	B-NP
O	1256	1258	mL	mL	NN	I-NP
O	1259	1262	and	and	CC	O
O	1263	1264	1	1	CD	B-NP
O	1265	1268	mug	mug	NN	I-NP
O	1268	1269	/	/	SYM	B-VP
O	1269	1271	mL	mL	NN	B-NP
O	1272	1286	concentrations	concentration	NNS	I-NP
O	1287	1291	were	be	VBD	B-VP
O	1292	1301	generated	generate	VBN	I-VP
O	1302	1307	using	use	VBG	B-VP
O	1308	1309	4	4	CD	B-NP
O	1310	1316	donors	donor	NNS	I-NP
O	1316	1317	.	.	.	O

O	1318	1322	Data	Datum	NNS	B-NP
O	1323	1326	for	for	IN	B-PP
O	1327	1330	the	the	DT	B-NP
O	1331	1337	higher	high	JJR	I-NP
O	1338	1341	and	and	CC	O
O	1342	1345	the	the	DT	B-NP
O	1346	1351	lower	low	JJR	I-NP
O	1352	1366	concentrations	concentration	NNS	I-NP
O	1367	1371	were	be	VBD	B-VP
O	1372	1381	generated	generate	VBN	I-VP
O	1382	1387	using	use	VBG	B-VP
O	1388	1389	2	2	CD	B-NP
O	1390	1396	donors	donor	NNS	I-NP
O	1396	1397	.	.	.	O

O	1398	1404	Figure	Figure	NN	B-NP
O	1405	1406	5	5	CD	I-NP

O	1407	1417	Inhibition	Inhibition	NN	B-NP
O	1418	1420	by	by	IN	B-PP
O	1421	1423	Ab	Ab	NN	B-NP
O	1423	1424	-	-	HYPH	O
O	1424	1426	01	01	CD	B-NP
O	1427	1429	at	at	IN	B-PP
O	1430	1433	the	the	DT	B-NP
O	1434	1443	indicated	indicate	VBN	I-NP
O	1444	1457	concentration	concentration	NN	I-NP
O	1458	1460	is	be	VBZ	B-VP
O	1461	1466	shown	show	VBN	I-VP
O	1467	1470	for	for	IN	B-PP
O	1471	1472	6	6	CD	B-NP
O	1473	1477	IL21	IL21	NN	I-NP
O	1477	1478	-	-	HYPH	B-NP
O	1478	1488	responsive	responsive	JJ	I-NP
O	1489	1494	genes	gene	NNS	I-NP
O	1494	1495	.	.	.	O

O	1496	1500	IC50	IC50	NN	B-NP
O	1501	1507	values	value	NNS	I-NP
O	1508	1510	of	of	IN	B-PP
O	1511	1521	inhibition	inhibition	NN	B-NP
O	1522	1528	curves	curve	NNS	I-NP
O	1529	1534	shown	show	VBN	B-VP
O	1535	1537	in	in	IN	B-PP
O	1538	1544	Figure	Figure	NN	B-NP
O	1545	1547	4A	4A	NN	I-NP
O	1548	1552	were	be	VBD	B-VP
O	1553	1563	calculated	calculate	VBN	I-VP
O	1564	1569	using	use	VBG	B-VP
O	1570	1575	curve	curve	NN	B-NP
O	1576	1579	fit	fit	NN	I-NP
O	1580	1581	(	(	(	O
O	1581	1586	XLfit	XLfit	NN	B-NP
O	1586	1587	)	)	)	O
O	1588	1595	program	program	NN	B-NP
O	1596	1599	for	for	IN	B-PP
O	1600	1604	each	each	DT	B-NP
O	1605	1607	of	of	IN	B-PP
O	1608	1611	the	the	DT	B-NP
O	1612	1620	referred	refer	VBN	I-NP
O	1621	1630	biomarker	biomarker	NN	I-NP
O	1631	1636	genes	gene	NNS	I-NP
O	1636	1637	.	.	.	O

O	1638	1644	Values	Value	NNS	B-NP
O	1645	1648	for	for	IN	B-PP
O	1649	1652	the	the	DT	B-NP
O	1653	1654	0	0	CD	I-NP
O	1654	1655	.	.	.	I-NP
O	1655	1656	1	1	CD	I-NP
O	1657	1660	mug	mug	NN	I-NP
O	1660	1661	/	/	SYM	B-NP
O	1661	1663	mL	mL	NN	I-NP
O	1663	1664	,	,	,	O
O	1665	1666	0	0	CD	B-NP
O	1666	1667	.	.	.	O
O	1667	1668	3	3	CD	B-NP
O	1669	1672	mug	mug	NN	I-NP
O	1672	1673	/	/	SYM	B-NP
O	1673	1675	mL	mL	NN	I-NP
O	1676	1679	and	and	CC	O
O	1680	1681	1	1	CD	B-NP
O	1682	1685	mug	mug	NN	I-NP
O	1685	1686	/	/	SYM	B-VP
O	1686	1688	mL	mL	NN	B-NP
O	1689	1703	concentrations	concentration	NNS	I-NP
O	1704	1708	were	be	VBD	B-VP
O	1709	1718	generated	generate	VBN	I-VP
O	1719	1724	using	use	VBG	B-VP
O	1725	1726	4	4	CD	B-NP
O	1727	1733	donors	donor	NNS	I-NP
O	1733	1734	.	.	.	O

O	1735	1739	Data	Datum	NNS	B-NP
O	1740	1743	for	for	IN	B-PP
O	1744	1747	the	the	DT	B-NP
O	1748	1754	higher	high	JJR	I-NP
O	1755	1758	and	and	CC	O
O	1759	1762	the	the	DT	B-NP
O	1763	1768	lower	low	JJR	I-NP
O	1769	1783	concentrations	concentration	NNS	I-NP
O	1784	1788	were	be	VBD	B-VP
O	1789	1798	generated	generate	VBN	I-VP
O	1799	1804	using	use	VBG	B-VP
O	1805	1806	2	2	CD	B-NP
O	1807	1813	donors	donor	NNS	I-NP
O	1814	1818	each	each	DT	B-NP
O	1818	1819	.	.	.	O

